Beta Drugs Reports Higher Consolidated and Standalone Net Profits in June 2026 Quarter
Beta Drugs reported a 35.04% increase in consolidated net profit to Rs 15.80 crore for the quarter ended June 2026, with sales rising 25.29% to Rs 125.55 crore. In contrast, its standalone net profit rose 40.19% to Rs 5.93 crore despite a 15.82% decline in sales to Rs 55.83 crore during the same period. Operating margins and profits before tax also showed growth in both consolidated and standalone results compared to June 2025.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (62/100). Lens Score 47/100.
Outlets measured: businessstandard, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (52–72/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 20 Jul, 07:11 am. Other outlets followed.
- 1